Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
1.590
-0.060 (-3.64%)
At close: Mar 5, 2026, 4:00 PM EST
1.570
-0.020 (-1.26%)
Pre-market: Mar 6, 2026, 9:11 AM EST
Milestone Pharmaceuticals Employees
Milestone Pharmaceuticals had 33 employees as of December 31, 2024. The number of employees decreased by 14 or -29.79% compared to the previous year.
Employees
33
Change (1Y)
-14
Growth (1Y)
-29.79%
Revenue / Employee
n/a
Profits / Employee
-$1,757,939
Market Cap
161.52M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| Innate Pharma | 174 |
| ProQR Therapeutics | 166 |
| Fate Therapeutics | 161 |
| Caribou Biosciences | 147 |
| Rani Therapeutics Holdings | 106 |
| Tenaya Therapeutics | 97 |
| Immunic | 90 |
MIST News
- 8 days ago - Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 24 days ago - Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer - GlobeNewsWire
- 4 weeks ago - Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - GlobeNewsWire
- 7 weeks ago - Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense - Seeking Alpha
- 2 months ago - Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency - GlobeNewsWire
- 2 months ago - Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment Transcript - Seeking Alpha
- 2 months ago - Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - GlobeNewsWire